You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 869 Venetoclax, a specific BCL-2 inhibitor, modulates CAR T cells genetically and functionally during production and augments their anti-tumor response

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
869 Venetoclax, a specific BCL-2 inhibitor, modulates CAR T cells genetically and functionally during production and augments their anti-tumor response

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Aboelella NS, Park R, Pan T, et al
869 Venetoclax, a specific BCL-2 inhibitor, modulates CAR T cells genetically and functionally during production and augments their anti-tumor response
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0869